News

Low post-transfusion platelet increments did not predict mortality or length of stay in pediatric patients.

Downey discusses the recent discovery of influenza’s interaction with the interferon 1 pathway, as well as a hypothetical method for preventing it.

The free, user-friendly calculator provides a 6-year lung cancer risk estimate to help patients and clinicians assess screening eligibility.

Survey findings highlight abdominal and bowel symptom control, affordability, and formulary or insurance coverage as factors driving perceptions and prescribing patterns of PERT.

Mark Kaufmann, MD, speaks on maximizing your billing effectiveness in the era of dwindling reimbursements and ICD-10.

Younossi explains the growing interest in NITs for MASLD and reviews his research on their performance in age, diabetes, and obesity subgroups.

Gonzalez explains how new findings in weather-related emergency department visits and pain in pediatric sickle cell disease can guide clinicians.

Rizik and Morris discuss the Heartflow PCI Navigator, which analyzes CT scans to generate 3D models of calcium blockages ahead of procedures.

In this Q&A, investigators Maria Byazrova and Rudolf Valenta discuss findings on plasmablast's role in seasonal IgE surge when it comes to birch allergy.

In this Q&A segment of his interview, Marghoob speaks on-site at Maui Derm on tips related to dermoscopy and skin cancer detection.

Desai discusses his recent observational cohort study indicating finerenone’s substantial reduction of heart failure exacerbation risk in patients with HFpEF.

The American Society of Hematology released new 2026 Guidelines for Management of Relapsed/Refractory ALL in AYAs, discussing immunotherapy and personalized decision making.

This interview with Marghoob was held on-site at Maui Derm, highlighting tips on dermoscopy and skin cancer detection from Marghoob’s workshop presentation.

Choi explains longstanding hesitancy around statin use in chronic liver disease, particularly cholestatic diseases like PBC, and how his research challenges these sentiments.

Wu discusses his recent study spotlighting food source and quality as a more significant influence on CHD risk compared to simply cutting carbs or fat.

Upstream Bio announced positive topline results from the phase 2 VALIANT trial evaluating the efficacy and safety of verekitug in adults with severe asthma.

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes.

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

In the opening segment of this special report, panelists discuss updated anaphylaxis guidelines and early management priorities.

In an interview with HCPLive, Emily Aman, MPH, and Rachel White, share that most marginalized children with uncontrolled asthma miss specialist visits despite caregiver support due to existing barriers.

Bress highlights the potential shortcomings of relying on the Apple Watch as a diagnostic tool for hypertension, discussing its potential for false negatives.

Choi describes existing evidence on statin use in patients with liver disease and reviews his new research about their potential utility in PBC.

These data highlight the impact of rezpegaldesleukin therapy on adults with moderate-to-severe atopic dermatitis in the phase 2b REZOLVE-AD study.

FDA grants Priority Review for Takeda’s oveporexton, an oral orexin agonist for narcolepsy type 1, showing near-normal symptom control in phase 3.

Positive topline data from Hengrui’s phase 2 clinical trial of once-daily oral ribupatide highlight weight loss of up to 12.1% with no observed plateau at 26 weeks.

Patients with severe hypertriglyceridemia and MASLD saw reductions in fasting triglyceride and improvements in remnant cholesterol and hepatic fat.